

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM713429

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	REASSIGNMENT AND RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
OXFORD FINANCE LLC		03/08/2022	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Xeris Pharmaceuticals, Inc.		
<b>Street Address:</b>	180 North LaSalle Street, Suite 1600		
<b>City:</b>	Chicago		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60601		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90359515	XERIJECT	
<b>Serial Number:</b>	90359499	XERISOL	
<b>Serial Number:</b>	90165932	GVOKE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	800-494-5225		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Stewart Walsh		
<b>Address Line 1:</b>	1025 Connecticut Ave NW, Suite 712		
<b>Address Line 2:</b>	COGENY GLOBAL Inc.		
<b>Address Line 4:</b>	Washington, D.C. 20036		
<b>ATTORNEY DOCKET NUMBER:</b>	1618821 TM Rel 2021		
<b>NAME OF SUBMITTER:</b>	Monet Zaccarelli		
<b>SIGNATURE:</b>	/Monet Zaccarelli/		
<b>DATE SIGNED:</b>	03/10/2022		
<b>Total Attachments: 12</b>			
source=Xeris - 2021 IP Release#page1.tif			

OP \$90.00 90359515

source=Xeris - 2021 IP Release#page2.tif  
source=Xeris - 2021 IP Release#page3.tif  
source=Xeris - 2021 IP Release#page4.tif  
source=Xeris - 2021 IP Release#page5.tif  
source=Xeris - 2021 IP Release#page6.tif  
source=Xeris - 2021 IP Release#page7.tif  
source=Xeris - 2021 IP Release#page8.tif  
source=Xeris - 2021 IP Release#page9.tif  
source=Xeris - 2021 IP Release#page10.tif  
source=Xeris - 2021 IP Release#page11.tif  
source=Xeris - 2021 IP Release#page12.tif

**REASSIGNMENT AND RELEASE OF SECURITY INTEREST**

This Reassignment and Release of Security Interest is executed as of March 8, 2022 (this “Release”) by OXFORD FINANCE LLC, as Collateral Agent (the “Collateral Agent”) for the benefit of XERIS PHARMACEUTICALS, INC., a Delaware corporation with offices located at 180 North LaSalle Street, Suite 1600, Chicago, IL 60601 (“Grantor”).

RECITALS

A. WHEREAS, Grantor granted and pledged certain security interests in the intellectual property described on Exhibit A (the “Patents”) and Exhibit B (the “Trademarks”) to the Collateral Agent pursuant to a certain Intellectual Property Security Agreement dated as of May 3, 2021 (the “Agreement”) and recorded on May 4, 2021 with the U.S. Patent and Trademark Office (the “USPTO”) (i) Patent Division at Reel/Frame 056135/0800 and (ii) Trademark Division Reel/Frame 7279/0400; and

B. WHEREAS, Collateral Agent wishes to release and reassign all interest that Collateral Agent may have in the Intellectual Property Collateral (as defined in the Agreement), including, without limitation, the Patents and Trademarks (the “Released Collateral”).

AGREEMENT

Now, therefore, Collateral Agent terminates the Agreement and releases, terminates and discharges fully all liens and security interests thereunder in Grantor’s right, title and interest in to and under the Released Collateral and authorizes and requests that this Release be recorded with the USPTO.

Address:

115 South Union Street, Suite 300  
Alexandria, Virginia 22314

COLLATERAL AGENT:

OXFORD FINANCE LLC


By:   
Name: Colette H. Featherly  
Title: Senior Vice President

EXHIBIT A

Patents

Country	Application Number	Application Date	Patent Number	Grant Date	Title/Full Mark Name
Armenia	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Australia	2012332556	10/31/2012	2012332556	09/08/2016	FORMULATIONS FOR THE TREATMENT OF DIABETES
Australia	2013284412	06/27/2013	2013284412	04/05/2018	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS
Australia	2018275686	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Australia	2018301715	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Australia	2018388417	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Australia	2019211352	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Austria	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Azerbaijan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Azerbaijan	201490913	10/31/2012	027744	08/31/2017	FORMULATIONS FOR THE TREATMENT OF DIABETES
Bahrain	20200009	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Belarus	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS

EAST\188663351.1

Brazil	BR11202000447-2	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Brazil	BR112020012268-8	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Brazil	BR112020014719-2	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Canada	3,064,840	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Canada	3,069,533	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
China	201610221799.6	03/09/2012	ZL201610221799.6	08/30/2019		STABLE FORMULATIONS FOR PARENTERAL INJECTION
China	201880036611.8	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
China	201880047057.3	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
China	201880083343.5	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
China	201980009791.5	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Colombia	NC2019/0013342	05/31/2018				PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Colombia	NC2020/0000529	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM

Denmark	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Denmark	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
EPC - European Patent Convention	21156886.0	08/06/2015			SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES
EPC - European Patent Convention	18733442.0	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
EPC - European Patent Convention	18749686.4	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
EPC - European Patent Convention	18837063.9	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
EPC - European Patent Convention	19196481.6	12/22/2003			FORMULATION FOR INTRACUTANEOUS INJECTION
EPC - European Patent Convention	19704169.2	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
France	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
France	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Germany	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Germany	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Ireland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Israel	270979	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS

Israel	271967	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Italy	12711071.6	03/09/2012	2683364	01/18/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Japan	2020-173883	08/06/2015			SYRINGES, KITS, AND METHODS FOR INTRACUTANEOUS AND/OR SUBCUTANEOUS INJECTION OF PASTES
Japan	2019-566327	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Japan	2020-501203	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Japan	2020-534601	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Japan	(To Be Determined)	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Kazakhstan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Korea, Republic of	10-2019-7035678	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Korea, Republic of	10-2020-7020257	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Korea, Republic of	10-2020-7022613	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON

Kyrgyzstan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Mexico	MX/a/2019/014486	05/31/2018			PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS
Mexico	MX/a/2020/000514	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Mexico	MX/a/2020/006658	12/21/2018			TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Mexico	MX/a/2020/007768	01/23/2019			TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Moldova, Republic of	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Netherland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION



PCT - Patent Cooperation Treaty	PCT/US2020/035172	05/29/2020				STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME
Poland	12798470.6	10/31/2012	2773331	02/10/2016		FORMULATIONS FOR THE TREATMENT OF DIABETES
Qatar	QA/202001/00031	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Russian Federation	201370178	03/09/2012	028572	12/29/2017		STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Saudi Arabia	520411047	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
Saudi Arabia	520412302	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
Saudi Arabia	520412487	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
Spain	12711071.6	03/09/2012	2683364	01/18/2017		STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS

Sweden	15706976.6	02/06/2015	3102184	01/30/2019	STABLE PEPTIDE FORMULATIONS AND METHODS FOR PREPARATION
Switzerland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
Tajikistan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
Tajikistan	201490913	10/31/2012	027744	08/31/2017	FORMULATIONS FOR THE TREATMENT OF DIABETES
Turkey	12798470.6	10/31/2012	12798470.6	02/10/2016	FORMULATIONS FOR THE TREATMENT OF DIABETES
Turkmenistan	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
United Arab Emirates	201370178	03/09/2012	028572	12/29/2017	STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS
United Arab Emirates	P6000062/20	07/14/2018			METHODS FOR TREATING CONGENITAL HYPERINSULINISM
United Kingdom of Great Britain and Northern Ireland	12180169.0	12/22/2003	2526996	09/11/2019	INTRACUTANEOUS INJECTION
United States of America	177215,449	03/29/2021			STABLE FORMULATIONS FOR PARENTERAL INJECTION OF PEPTIDE DRUGS

United States of America	16/945,598	07/31/2020				STABLE FORMULATIONS FOR PARENTERAL INJECTION OF SMALL MOLECULE DRUGS
United States of America	16/600,722	10/14/2019				METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS
United States of America	16/630,774	07/14/2018				METHODS FOR TREATING CONGENITAL HYPERINSULINISM
United States of America	16/955,698	12/21/2018				TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES
United States of America	16/964,124	01/23/2019				TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON
United States of America	16/888,028	05/29/2020				STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME
United States of America	63/044,973	06/26/2020				STABLE SUBSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME

EAST\188663351.1

- 9 -

EXHIBIT B

Trademarks

<b>Mark</b>	<b>Country</b>	<b>Status</b>	<b>Appl. No.</b>	<b>Appl. Date</b>	<b>Reg. No.</b>	<b>Reg. Date</b>
OGLUO	European Union	REGISTERED	18288558	08/12/2020	18288558	01/08/2021
GVOKE logo	International Bureau of the World Intellectual Property Organization (WIPO)	PENDING	A0106151	03/05/2021		
XERIJECT	U.S.	PENDING	90/359,515	12/04/2020		
XERISOL	U.S.	PENDING	90/359,499	12/04/2020		
GVOKE logo	U.S.	PENDING	90/165,932	09/08/2020		
GLUCAXER	United Kingdom	REGISTERED	UK009017884655	04/06/2018	UK009017884655	08/29/2018
GLUCAXER HYPOPEN	United Kingdom	REGISTERED	UK009017884652	04/06/2018	UK009017884652	08/29/2018
GVOKE	United Kingdom	REGISTERED	UK0081462300	12/19/2018	UK0081462300	12/19/2018

Mark	Country	Status	Appl. No.	Appl. Date	Reg. No.	Reg. Date
GVOKE HYOPEN	United Kingdom	REGISTERED	UK0081462159	12/19/2018	UK0081462159	12/19/2018
HYOPEN	United Kingdom	REGISTERED	UK009017923552	06/27/2018	UK009017923552	11/29/2018
XERIJECT	United Kingdom	REGISTERED	UK009017459199	11/10/2017	UK009017459199	03/12/2018
XERISOL	United Kingdom	REGISTERED	UK009017459173	11/10/2017	UK009017459173	03/12/2018
OGLUO	United Kingdom	REGISTERED	3521904	08/12/2020	3521904	11/27/2020